Healthcare providers have shown a lack of progress regarding ICD-10 readiness compared with a year ago, while vendors are mostly prepared, according to a new WEDI survey.
Healthcare providers have shown a lack of progress regarding ICD-10 preparedness compared with a year ago, according to the latest survey from the Workgroup for Electronic Data Interchange (WEDI).
WEDI has been conducting surveys on ICD-10 readiness since 2009 to gauge industry progress. This most recent survey found vendors are mostly prepared with just one-tenth halfway or less than halfway complete with product development. Compared with last year’s survey, nearly twice as many vendors indicated that their products are already available, while a quarter said their products would not be available until 2015 or an unknown date.
“Based on the survey results, all industry segments appear to have made some progress since October 2013, but the lack of progress by providers, in particular smaller ones, remains a cause for concern as we move toward the compliance deadline,” Jim Daley, WEDI chairman and ICD-10 Workgroup co-chair, said in a statement.
In the October 2013 survey three-fifths of providers had expected to begin external testing by the middle of 2014; however, according to this survey just one-third have actually done so. Now, more than half expect they will not begin external testing until 2015 or an unknown time.
The status of external testing varies greatly depending on the size of the provider organization. More than half of large providers have begun external testing, while most smaller providers do not plan to begin until 2015.
“Delaying compliance efforts reduces the time available for adequate testing, increasing the chances of unanticipated impacts to production,” Daley said. “We urge the industry to accelerate implementation efforts in order to avoid disruption on Oct. 1, 2015.”
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More